Century Therapeutics Q3 net loss narrows, beats analyst expectations
IPSC•Century Therapeutics reported a third-quarter net loss of $23.45 million, beating the $24.25 million analyst estimate, while operating income missed expectations. The company expects to submit an IND for CNTY-813 in the fourth quarter of 2026 and estimates its cash runway into the first quarter of 2029.
1. Quarterly results
Century Therapeutics reported a third-quarter net loss of $23.45 million, compared with the $24.25 million analyst estimate. Operating income was a loss of $25.21 million, missing the $24.71 million expected loss, and loss per basic share was $0.11. The company said lower research and development expenses reflected reduced personnel and facility costs following portfolio prioritization.
2. Pipeline and cash
Century expects to submit an investigational new drug application for CNTY-813 in the fourth quarter of 2026 and anticipates initial clinical data in the second half of 2027. It estimates its cash runway will extend into the first quarter of 2029.
